Evidence map›Paper›PMID 36383652›Full record

ArticleScience advances2022

CTR9 drives osteochondral lineage differentiation of human mesenchymal stem cells via epigenetic regulation of BMP-2 signaling.

Ngai Ting Chan, Ming-Song Lee, Yidan Wang, Jacques Galipeau, Wan-Ju Li, Wei Xu

Open access · goldAbstract read
In one paragraph

Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ngai Ting ChanMcArdle Laboratory for Cancer Research, Wisconsin Institute for Medical Research, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI 53706, USA.ORCID 0000-0002-6203-9109
Ming-Song LeeDepartment of Orthopedics and Rehabilitation, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53706, USA.ORCID 0000-0001-7660-1900
Yidan WangMcArdle Laboratory for Cancer Research, Wisconsin Institute for Medical Research, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI 53706, USA.ORCID 0000-0002-1417-8059
Jacques GalipeauDepartment of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53706, USA.ORCID 0000-0002-9374-1996
Wan-Ju LiDepartment of Orthopedics and Rehabilitation, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53706, USA.ORCID 0000-0002-6579-8063
Wei XuMcArdle Laboratory for Cancer Research, Wisconsin Institute for Medical Research, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI 53706, USA.ORCID 0000-0003-3808-0045
University of Wisconsin Carbone Cancer Center · USUniversity of Wisconsin–Madison · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
Protein Arginine Methylation in Breast CancerR01CA236356 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Wei Xu · 2019 to 2026
$2.9M
Ctr9 as a Predictive Biomarker for EZH2 Inhibitor SensitivityR01CA268183 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Wei Xu · 2022 to 2026
$2.0M
Blood-derived Induced Pluripotent Stem Cells for Cartilage RepairR01AR064803 · NIAMS · UNIVERSITY OF WISCONSIN-MADISON · PI LI, WAN-JU · 2015 to 2019
$1.6M
Protein Arginine Methylation in Chemotherapy ResistanceR01CA213293 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI XU, WEI · 2017 to 2021
$795k
NCI NIH HHS P30 CA014520NCI NIH HHS R01 CA213293NCI NIH HHS R01 CA236356NCI NIH HHS R01 CA268183NIAMS NIH HHS R01 AR064803
6 · The paper itself

Abstract

Cell fate determination of human mesenchymal stem/stromal cells (hMSCs) is precisely regulated by lineage-specific transcription factors and epigenetic enzymes. We found that CTR9, a key scaffold subunit of polymerase-associated factor complex (PAFc), selectively regulates hMSC differentiation to osteoblasts and chondrocytes, but not to adipocytes. An in vivo ectopic osteogenesis assay confirmed the essentiality of CTR9 in hMSC-derived bone formation. CTR9 counteracts the activity of Enhancer Of Zeste 2 (EZH2), the epigenetic enzyme that deposits H3K27me3, in hMSCs. Accordingly, CTR9 knockdown (KD) hMSCs gain H3K27me3 mark, and the osteogenic differentiation defects of CTR9 KD hMSCs can be partially rescued by treatment with EZH2 inhibitors. Transcriptome analyses identified bone morphology protein-2 (BMP-2) as a downstream effector of CTR9. BMP-2 secretion, membrane anchorage, and the BMP-SMAD pathway were impaired in CTR9 KD MSCs, and the effects were rescued by BMP-2 supplementation. This study uncovers an epigenetic mechanism engaging the CTR9-H3K27me3-BMP-2 axis to regulate the osteochondral lineage differentiation of hMSCs.

Indexed as

Mesenchymal Stem CellsOsteogenesisCell DifferentiationEpigenesis, GeneticHistonesHumansOsteoblastsPhosphoproteinsTranscription FactorsCTR9 protein, humanHistonesPhosphoproteinsTranscription Factors

Identifiers

PMID36383652
PMCPMC9668309
OpenAlexW4309156289

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.